These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 12702725)
1. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. Kusu N; Laurikkala J; Imanishi M; Usui H; Konishi M; Miyake A; Thesleff I; Itoh N J Biol Chem; 2003 Jun; 278(26):24113-7. PubMed ID: 12702725 [TBL] [Abstract][Full Text] [Related]
2. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. Okamoto M; Murai J; Yoshikawa H; Tsumaki N J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523 [TBL] [Abstract][Full Text] [Related]
3. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355 [TBL] [Abstract][Full Text] [Related]
4. Identification of a secreted BMP antagonist, ectodin, integrating BMP, FGF, and SHH signals from the tooth enamel knot. Laurikkala J; Kassai Y; Pakkasjärvi L; Thesleff I; Itoh N Dev Biol; 2003 Dec; 264(1):91-105. PubMed ID: 14623234 [TBL] [Abstract][Full Text] [Related]
5. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. Krause C; Korchynskyi O; de Rooij K; Weidauer SE; de Gorter DJ; van Bezooijen RL; Hatsell S; Economides AN; Mueller TD; Löwik CW; ten Dijke P J Biol Chem; 2010 Dec; 285(53):41614-26. PubMed ID: 20952383 [TBL] [Abstract][Full Text] [Related]
6. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. Winkler DG; Sutherland MK; Geoghegan JC; Yu C; Hayes T; Skonier JE; Shpektor D; Jonas M; Kovacevich BR; Staehling-Hampton K; Appleby M; Brunkow ME; Latham JA EMBO J; 2003 Dec; 22(23):6267-76. PubMed ID: 14633986 [TBL] [Abstract][Full Text] [Related]
7. Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis. Ohyama Y; Nifuji A; Maeda Y; Amagasa T; Noda M Endocrinology; 2004 Oct; 145(10):4685-92. PubMed ID: 15217980 [TBL] [Abstract][Full Text] [Related]
8. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. Choi HY; Dieckmann M; Herz J; Niemeier A PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252 [TBL] [Abstract][Full Text] [Related]
9. Brorin, a novel secreted bone morphogenetic protein antagonist, promotes neurogenesis in mouse neural precursor cells. Koike N; Kassai Y; Kouta Y; Miwa H; Konishi M; Itoh N J Biol Chem; 2007 May; 282(21):15843-50. PubMed ID: 17400546 [TBL] [Abstract][Full Text] [Related]
10. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. van Bezooijen RL; Roelen BA; Visser A; van der Wee-Pals L; de Wilt E; Karperien M; Hamersma H; Papapoulos SE; ten Dijke P; Löwik CW J Exp Med; 2004 Mar; 199(6):805-14. PubMed ID: 15024046 [TBL] [Abstract][Full Text] [Related]
11. Estrogen Modulates Bone Morphogenetic Protein-Induced Sclerostin Expression Through the Wnt Signaling Pathway. Kim RY; Yang HJ; Song YM; Kim IS; Hwang SJ Tissue Eng Part A; 2015 Jul; 21(13-14):2076-88. PubMed ID: 25837159 [TBL] [Abstract][Full Text] [Related]
12. The role of BMPs in bone anabolism and their potential targets SOST and DKK1. Kamiya N Curr Mol Pharmacol; 2012 Jun; 5(2):153-63. PubMed ID: 21787290 [TBL] [Abstract][Full Text] [Related]
13. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. Winkler DG; Yu C; Geoghegan JC; Ojala EW; Skonier JE; Shpektor D; Sutherland MK; Latham JA J Biol Chem; 2004 Aug; 279(35):36293-8. PubMed ID: 15199066 [TBL] [Abstract][Full Text] [Related]
14. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm. van Bezooijen RL; Papapoulos SE; Löwik CW J Endocrinol Invest; 2005; 28(8 Suppl):15-7. PubMed ID: 16323824 [TBL] [Abstract][Full Text] [Related]
15. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. Winkler DG; Sutherland MS; Ojala E; Turcott E; Geoghegan JC; Shpektor D; Skonier JE; Yu C; Latham JA J Biol Chem; 2005 Jan; 280(4):2498-502. PubMed ID: 15545262 [TBL] [Abstract][Full Text] [Related]
16. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. van Bezooijen RL; Svensson JP; Eefting D; Visser A; van der Horst G; Karperien M; Quax PH; Vrieling H; Papapoulos SE; ten Dijke P; Löwik CW J Bone Miner Res; 2007 Jan; 22(1):19-28. PubMed ID: 17032150 [TBL] [Abstract][Full Text] [Related]
17. Involvement of endogenous bone morphogenetic protein (BMP) 2 and BMP6 in bone formation. Kugimiya F; Kawaguchi H; Kamekura S; Chikuda H; Ohba S; Yano F; Ogata N; Katagiri T; Harada Y; Azuma Y; Nakamura K; Chung UI J Biol Chem; 2005 Oct; 280(42):35704-12. PubMed ID: 16109715 [TBL] [Abstract][Full Text] [Related]
18. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572 [TBL] [Abstract][Full Text] [Related]
19. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Kamiya N; Ye L; Kobayashi T; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y Development; 2008 Nov; 135(22):3801-11. PubMed ID: 18927151 [TBL] [Abstract][Full Text] [Related]
20. Molecular profiling of bone remodeling occurring in musculoskeletal tumors. Nakajima K; Kidani T; Miura H J Orthop Res; 2021 Jul; 39(7):1402-1410. PubMed ID: 33034913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]